UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 28, 2026

OR

TRANSITION REPORT PURSUANT TO SECTION 13

OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.

(Exact name of registrant as specified in its charter)

Delaware13-5315170

(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York 10001-2192

(Address of principal executive offices) (zip code)

(212) 733-2323

(Registrant s telephone number including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each classTrading Symbol(s)Name of each exchange on which registered

Common Stock, $0.05 par valuePFENew York Stock Exchange

1.000% Notes due 2027PFE/27

New York Stock Exchange

2.875% Notes due 2029

PFE/29

New York Stock Exchange

3.250% Notes due 2032

PFE/32

New York Stock Exchange

3.875% Notes due 2037

PFE/37A

New York Stock Exchange

4.250% Notes due 2045

PFE/45

New York Stock Exchange

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T ( 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x Accelerated filer Non-accelerated filer Smaller reporting company Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes Nox

At July 29, 2026, 5,699,673,589 shares of the issuer s voting common stock were outstanding.

TABLE OF CONTENTS

PART I. FINANCIAL INFORMATION

Page

Item 1.

Financial Statements

Condensed Consolidated Statements of Operations

Condensed Consolidated Statements of Comprehensive Income/(Loss)

Condensed Consolidated Balance Sheets

Condensed Consolidated Statements of Equity

Condensed Consolidated Statements of Cash Flows

Notes to Condensed Consolidated Financial Statements

10

Item 2.

Management s Discussion and Analysis of Financial Condition and Results of Operations

34

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

51

Item 4.

Controls and Procedures

51

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

52

Item 1A.

Risk Factors

52

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

52

Item 3.

Defaults Upon Senior SecuritiesN/A

Item 4.

Mine Safety DisclosuresN/A

Item 5.

Other Information

52

Item 6.

Exhibits

53

Signature

53

N/A = Not Applicable

DEFINED TERMS

Unless the context requires otherwise, references to Pfizer, the Company, we, us or our in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 24, 2026 and May 25, 2025, and for U.S. subsidiaries is as of and for the three and six months ended June 28, 2026 and June 29, 2025. References to Notes in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2025 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:

Indicates calculation not meaningful or results are greater than 100%

2025 Form 10-K

Annual Report on Form 10-K for the fiscal year ended December 31, 2025

340B Program340B Drug Pricing Program

3SBio3SBio, Inc. and its subsidiaries Shenyang Sunshine Pharmaceutical Co., Ltd. and 3S Guojian Pharmaceutical (Shanghai) Co., Ltd.

AbingworthAbingworth LLP

AIartificial intelligence

ALKanaplastic lymphoma kinase

Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us

AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.

ATTR-CMtransthyretin amyloid cardiomyopathy

BioNTechBioNTech SE

BiopharmaGlobal Biopharmaceuticals Business

BMSBristol-Myers Squibb Company

BODBoard of Directors

CODMChief Operating Decision Maker

ComirnatyUnless otherwise noted, refers to, as applicable, the current formulation of Comirnaty (COVID-19 Vaccine, mRNA) 2026-2027(a) Formula as well as all prior authorized or approved formulations of the vaccine, which was first authorized in the U.S. during December 2020 pursuant to an EUA

COVID-19novel coronavirus disease of 2019

Developed MarketsIncludes, but is not limited to, the following markets: Western Europe, Japan, Central Europe, Canada, Australia, Nordic countries, certain Eastern European countries, South Korea and New Zealand

EMAEuropean Medicines Agency

Emerging MarketsIncludes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe (excluding the Balkans and certain other countries), Africa, the Middle East and Turkey

EPSearnings per share

EUEuropean Union

EUAemergency use authorization

Exchange ActSecurities Exchange Act of 1934, as amended

FASBFinancial Accounting Standards Board

FDAU.S. Food and Drug Administration

Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended June 28, 2026

GAAPU.S. Generally Accepted Accounting Principles

GILTI (NCTI)Global Intangible Low-Taxed Income (renamed Net Controlled Foreign Corporation (CFC) Tested Income (NCTI) for taxable years starting after December 31, 2025)

GSKGSK plc

HaleonHaleon plc

HRRhomologous recombination repair

InnoventInnovent Biologics, Inc.

IPR&Din-process research and development

IRAInflation Reduction Act of 2022

IRSU.S. Internal Revenue Service

JVjoint venture

KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)

LPSloss per share

mCCmetastatic cervical cancer

mCRCmetastatic colorectal cancer

mCRPCmetastatic castration-resistant prostate cancer

mCSPCmetastatic castration-sensitive prostate cancer

MD&AManagement s Discussion and Analysis of Financial Condition and Results of Operations

MDLMulti-District Litigation

Medicare Part Da prescription drug coverage program for people with Medicare

MetseraMetsera, Inc.

MIBCmuscle-invasive bladder cancer

Moody sMoody s Ratings (formerly Moody s Investors Service)

mRNAmessenger ribonucleic acid

nmCRPCnon-metastatic castration-resistant prostate cancer

nmCSPCnon-metastatic castration-sensitive prostate cancer

NSCLCnon-small cell lung cancer

OBBBAOne Big Beautiful Bill Act

ODToral disintegrating tablet

OTCover-the-counter

Paxlovid(b)

an oral COVID-19 treatment (nirmatrelvir tablets and ritonavir tablets)

PC1Pfizer CentreOne

PharmaciaPharmacia LLC (formerly Pharmacia Corporation)

Prevnar familyIncludes Prevnar 20/Prevenar 20 (pediatric and adult) and Prevnar 13/Prevenar 13 (pediatric and adult)

PsApsoriatic arthritis

QTDQuarter-to-date or three months ended

RArheumatoid arthritis

R&Dresearch and development

RSVrespiratory syncytial virus

S&PS&P Global (formerly Standard & Poor s)

SCDsickle cell disease

Sciwind Biosciences

Hangzhou Sciwind Biosciences Co., Ltd.

SeagenSeagen Inc. and its subsidiaries

SECU.S. Securities and Exchange Commission

SI&ASelling, informational and administrative expenses

TakedaTakeda Pharmaceutical Company Limited

Tax Cuts and Jobs Act or TCJALegislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017

UCulcerative colitis

U.K.United Kingdom

U.S.United States

ViiVViiV Healthcare Limited

Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac

WyethWyeth LLC (formerly Wyeth)

YaoPharmaYaoPharma Co., Ltd.

YTDYear-to-date or six months ended

(a)Approved by the European Commission and pending approval in the U.S.

(b)Paxlovid has not been approved, but has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency use of Paxlovid in the relevant pediatric population is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the U.S. Federal Food, Drug and Cosmetics Act, 21 U.S.C. 360bbb-3(b)(1). On June 30, 2026, the U.S. Department of Health and Human Services announced the termination of the COVID-19 EUA declarations for drugs and biological products, effective June 29, 2027. Please see the EUA Fact Sheet at www.covid19oralrx.com.

This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or efficacy of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.

Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.

The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our X accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.

Certain of the products and product candidates discussed in this Form 10-Q are being co-researched, co-developed and/or co-promoted in collaboration with other companies for which Pfizer s rights vary by market or are the subject of agreements pursuant to which Pfizer has commercialization rights in certain markets.

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(UNAUDITED)

Three Months EndedSix Months Ended

(MILLIONS, EXCEPT PER SHARE DATA)June 28,

2026June 29,

2025June 28,

2026June 29,

2025

Revenues:

Product revenues

$11,863 $11,954 $23,578 $23,248

Alliance revenues

2,697 2,273 5,036 4,386

Royalty revenues

474 426 870 734

Total revenues15,034 14,653 29,484 28,367

Costs and expenses:

Cost of sales(a)

4,092 3,778 7,640 6,624

Selling, informational and administrative expenses(a)

3,411 3,415 6,372 6,446

Research and development expenses(a)

2,809 2,482 5,299 4,685

Acquired in-process research and development expenses16 2 153 11

Amortization of intangible assets1,185 1,211 2,368 2,421

Restructuring charges and certain acquisition-related costs457 (18)557 660

Other (income)/deductions net3,716 739 4,577 1,692

Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)(653)3,044 2,517 5,828

Provision/(benefit) for taxes on income/(loss)(407)141 54 (48)

Income/(loss) from continuing operations(246)2,903 2,463 5,876

Discontinued operations net of tax8 25 (5)25

Net income/(loss) before allocation to noncontrolling interests(237)2,928 2,458 5,901

Less: Net income attributable to noncontrolling interests10 18 19 24

Net income/(loss) attributable to Pfizer Inc. common shareholders$(248)$2,910 $2,440 $5,877

Earnings/(loss) per common share basic:

Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders$(0.04)$0.51 $0.43 $1.03

Discontinued operations net of tax

Net income/(loss) attributable to Pfizer Inc. common shareholders$(0.04)$0.51 $0.43 $1.03

Earnings/(loss) per common share diluted:

Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders$(0.04)$0.51 $0.43 $1.03

Discontinued operations net of tax

Net income/(loss) attributable to Pfizer Inc. common shareholders$(0.04)$0.51 $0.43 $1.03

Weighted-average shares basic5,699 5,685 5,695 5,680

Weighted-average shares diluted5,699 5,706 5,733 5,708

(a) Exclusive of amortization of intangible assets.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME/(LOSS)

(UNAUDITED)

Three Months EndedSix Months Ended

(MILLIONS)June 28,

2026June 29,

2025June 28,

2026June 29,

2025

Net income/(loss) before allocation to noncontrolling interests$(237)$2,928 $2,458 $5,901

Foreign currency translation adjustments, net(41)127 882 (430)

Unrealized holding gains/(losses) on derivative financial instruments, net121 (273)85 (395)

Reclassification adjustments for (gains)/losses included in net income/(loss)(a)

(11)(106)(2)(419)

110 (379)83 (814)

Unrealized holding gains/(losses) on available-for-sale securities, net(57)166 (19)135

Reclassification adjustments for (gains)/losses included in net income/(loss)(b)

22 (83)43 72

(36)82 24 207

Reclassification adjustments related to amortization of prior service costs and other, net(6)(24)(13)(55)

Reclassification adjustments related to curtailments of prior service costs and other, net (11)(4)(44)

(6)(35)(18)(99)

Other comprehensive income/(loss), before tax27 (204)970 (1,136)

Tax provision/(benefit) on other comprehensive income/(loss)53 (347)134 (538)

Other comprehensive income/(loss) before allocation to noncontrolling interests$(26)$143 $837 $(598)

Comprehensive income/(loss) before allocation to noncontrolling interests$(264)$3,071 $3,295 $5,303

Less: Comprehensive income/(loss) attributable to noncontrolling interests(1)18 4 22

Comprehensive income/(loss) attributable to Pfizer Inc.$(263)$3,053 $3,291 $5,282

(a)Reclassified into Other (income)/deductions net and Cost of sales. See Note 7E.

(b)Reclassified into Other (income)/deductions net.

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(MILLIONS)June 28,

2026December 31, 2025

(Unaudited)

Assets

Cash and cash equivalents$976 $1,142

Short-term investments10,723 12,454

Trade accounts receivable, net of allowance for doubtful accounts: 2026 $423; 2025 $427

12,490 11,874

Inventories9,945 10,654

Current tax assets3,702 3,967

Other current assets3,522 2,808

Total current assets41,358 42,898

Long-term investments1,559 1,621

Property, plant and equipment, net of accumulated depreciation: 2026 $18,104; 2025 $17,386

19,029 19,317

Identifiable intangible assets, net

47,053 53,731

Goodwill71,419 71,264

Noncurrent deferred tax assets and other noncurrent tax assets10,774 9,699

Other noncurrent assets9,939 9,631

Total assets$201,131 $208,160

Liabilities and Equity

Short-term borrowings, including current portion of long-term debt: 2026 $2,605; 2025 $2,997

$2,699 $3,154

Trade accounts payable4,581 5,240

Dividends payable2,451 2,445

Income taxes payable653 3,103

Accrued compensation and related items2,554 3,610

Other current liabilities19,709 19,432

Total current liabilities32,646 36,984

Long-term debt60,495 61,641

Pension and postretirement benefit obligations1,937 2,041

Noncurrent deferred tax liabilities1,964 2,401

Other taxes payable3,816 3,591

Other noncurrent liabilities14,780 14,725

Total liabilities115,639 121,385

Commitments and Contingencies

Common stock482 481

Additional paid-in capital95,033 94,469

Treasury stock(115,194)(115,015)

Retained earnings112,087 114,610

Accumulated other comprehensive loss(7,218)(8,069)

Total Pfizer Inc. shareholders equity85,190 86,476

Equity attributable to noncontrolling interests302 299

Total equity85,492 86,775

Total liabilities and equity$201,131 $208,160

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(UNAUDITED)

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, March 29, 20269,641 $482 $94,773 (3,942)$(115,190)$117,238 $(7,203)$90,101 $303 $90,404

Net income/(loss)(248)(248)10 (237)

Other comprehensive income/(loss), net of tax

(15)(15)(11)(26)

Cash dividends declared, per share: $0.86

Common stock(4,902)(4,902)(4,902)

Share-based payment transactions 259 (4)(1)254 254

Other (1)

Balance, June 28, 20269,641 $482 $95,033 (3,942)$(115,194)$112,087 $(7,218)$85,190 $302 $85,492

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, March 30, 20259,620 $481 $93,856 (3,935)$(115,008)$119,590 $(8,581)$90,338 $299 $90,637

Net income/(loss)2,910 2,910 18 2,928

Other comprehensive income/(loss), net of tax143 143 143

Cash dividends declared, per share: $0.86

Common stock (4,890)(4,890)(4,890)

Share-based payment transactions 197 (2)(1)195 195

Other (1)(1) (1)

Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20269,621 $481 $94,469 (3,935)$(115,015)$114,610 $(8,069)$86,476 $299 $86,775

Net income/(loss)2,440 2,440 19 2,458

Other comprehensive income/(loss), net of tax852 852 (15)837

Cash dividends declared, per share: $0.86

Common stock(4,902)(4,902)(4,902)

Share-based payment transactions20 1 564 (7)(179)(61)324 324

Other

Balance, June 28, 20269,641 $482 $95,033 (3,942)$(115,194)$112,087 $(7,218)$85,190 $302 $85,492

PFIZER INC. SHAREHOLDERS

Common StockTreasury Stock

(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd l

Paid-In CapitalSharesCostRetained EarningsAccum. Other Comp.

LossShare-

holders EquityNon-controlling interestsTotal Equity

Balance, January 1, 20259,593 $480 $93,603 (3,926)$(114,763)$116,725 $(7,842)$88,203 $294 $88,497

Net income/(loss)5,877 5,877 24 5,901

Other comprehensive income/(loss), net of tax(596)(596)(3)(598)

Cash dividends declared, per share: $0.86

Common stock (4,890)(4,890)(4,890)

Share-based payment transactions28 1 450 (9)(246)(104)101 101

Other 2 2

Balance, June 29, 20259,620 $481 $94,053 (3,935)$(115,010)$117,609 $(8,438)$88,695 $317 $89,012

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

Six Months Ended

(MILLIONS)June 28,

2026June 29,

2025

Operating Activities

Net income before allocation to noncontrolling interests$2,458 $5,901

Discontinued operations net of tax(5)25

Net income from continuing operations before allocation to noncontrolling interests2,463 5,876

Adjustments to reconcile net income from continuing operations before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:

Depreciation and amortization3,235 3,243

Asset write-offs and impairments4,425 498

Deferred taxes(1,332)(935)

Share-based compensation expense521 373

Benefit plan contributions in excess of expense/income(285)(334)

Net gain from the sale of investment in ViiV(1,870)

Other adjustments, net(159)(61)

Other changes in assets and liabilities, net of acquisitions and divestitures(3,548)(6,908)

Net cash provided by/(used in) operating activities3,450 1,753

Investing Activities

Purchases of property, plant and equipment(969)(1,182)

Purchases of short-term investments(5,113)(6,085)

Proceeds from redemptions/sales of short-term investments6,614 10,500

Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less386 (2,668)

Purchases of long-term investments(95)(86)

Proceeds from redemptions/sales of long-term investments172 145

Proceeds from the sale of investment in ViiV1,875

Proceeds from sales of investment in Haleon

6,311

Other investing activities, net21 288

Net cash provided by/(used in) investing activities2,891 7,225

Financing Activities

Payments on short-term borrowings (2,199)

Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less

(63)(903)

Proceeds from issuance of long-term debt 3,687

Payments on long-term debt(1,250)(3,750)

Cash dividends paid(4,896)(4,882)

Other financing activities, net(311)(377)

Net cash provided by/(used in) financing activities(6,519)(8,423)

Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents

15 34

Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents(164)588

Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period1,197 1,107

Cash and cash equivalents and restricted cash and cash equivalents, at end of period$1,034 $1,694

Supplemental Cash Flow Information

Cash paid during the period for:

Income taxes

$3,539 $3,493

Interest paid

1,541 1,483

Interest rate hedges4 29

See Accompanying Notes.

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies

A. Basis of Presentation

We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2025 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.

These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2025 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.

Pfizer s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 24, 2026 and May 25, 2025, and for U.S. subsidiaries is as of and for the three and six months ended June 28, 2026 and June 29, 2025.

We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and PC1. Biopharma is the only reportable segment. See Note 13A.

B. Revenues and Trade Accounts Receivable

Deductions from Revenues Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:

(MILLIONS)June 28,

2026December 31, 2025

Reserve against Trade accounts receivable, net of allowance for doubtful accounts

$1,741 $1,803

Other current liabilities:

Accrued rebates9,293 7,909

Other accruals763 750

Other noncurrent liabilities

332 1,204

Total accrued rebates and other sales-related accruals$12,128 $11,666

Trade Accounts Receivable Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market, delinquency status, and customer type (high risk versus low risk and government versus non-government), and reserve percentages are established for each pool of trade accounts receivables.

In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.

During the three and six months ended June 28, 2026 and June 29, 2025, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements.

For additional information on our trade accounts receivable, see Note 1G in our 2025 Form 10-K.

Note 2. Acquisition, In-Licensing Arrangement, Sale of Investment and Research and Development Arrangement

A. Acquisition

Metsera On November 13, 2025, we acquired Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases, for $65.60 per share in cash plus a contingent value right (CVR) of up to $20.65 per share in potential additional payments (up to $2.3 billion) tied to the achievement of three specified milestones: $4.60 per share following the Phase 3 clinical trial start of Metsera s injectable GLP-1 receptor antagonist MET-097i+amylin analog MET-233i combination, $6.40 per share following FDA approval of Metsera s monthly MET-097i monotherapy and $9.65 per share following FDA approval of Metsera s monthly MET-097i+MET-233i combination. The total

10

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

fair value of the consideration transferred was $8.0 billion ($7.8 billion net of cash acquired), which includes the fair value of $632 million for the CVRs and $475 million for employee stock awards related to pre-acquisition service.

In connection with this business combination, we provisionally recorded: (i) $7.9 billion of identifiable intangible assets, net, consisting of IPR&D, (ii) $2.1 billion of Goodwill, (iii) $1.6 billion of net deferred tax liabilities, and (iv) $643 million of contingent consideration liability assumed from Metsera. Goodwill, which resulted primarily from the recognition of deferred tax liabilities, is related to our Biopharma segment and is not deductible for tax purposes. The contingent consideration liability was recorded at fair value and relates to Metsera s 2023 acquisition of Zihipp Ltd (Zihipp). As a part of that transaction, the former Zihipp shareholders are entitled to future potential development, regulatory and commercialization milestone payments, along with low-single digit royalties on net product sales on the MET-097i and MET-233i product candidates. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.

B. In-Licensing Arrangement

In-Licensing Arrangement with Sciwind Biosciences In February 2026, Pfizer and Sciwind Biosciences announced a strategic commercialization collaboration in which Pfizer obtained exclusive commercialization rights for Sciwind Biosciences glucagon-like peptide 1 (GLP-1) receptor agonist ecnoglutide in Mainland China. Sciwind Biosciences remains the Marketing Authorization Holder and is responsible for R&D, registration, manufacturing and supply of the product. Sciwind Biosciences is eligible to receive an aggregate of up to $495 million in upfront, regulatory and sales milestone payments.

C. Sale of Investment

Sale of Investment in ViiV On March 31, 2026, which fell in our second fiscal quarter of 2026, Pfizer completed the exit of its 11.7% investment in ViiV. We received $1.875 billion in cash proceeds. See Note 4 and Note 2C in our 2025 Form 10-K.

Dividend income from our investment in ViiV, recorded in Other (income)/deductions net, was $98 million and $73 million for the three months ended June 28, 2026 and June 29, 2025, respectively, and $180 million and $111 million for the six months ended June 28, 2026 and June 29, 2025, respectively (see Note 4).

D. Research and Development Arrangement

Research and Development Funding Arrangement with Abingworth In June 2026, we entered into an arrangement with Abingworth under which we will receive up to a total of $300 million in 2026 through 2029 to co-fund our quarterly development costs for a specified treatment. As there is a substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. The reduction to Research and development expenses for the second quarter of 2026 was $26 million. If successful, upon regulatory approval in the U.S. for the indication based on the applicable clinical trial, Abingworth will be eligible to receive an approval-based milestone payment of up to $180 million, contingent upon the successful results of the clinical trial and payable over a period of approximately eighteen months. Following potential regulatory approval, Abingworth will be eligible to receive sales-based milestone payments of up to $420 million in total, based on the achievement of certain levels of cumulative applicable net sales and payable over a period of approximately three years, as well as royalties based on mid-single digit percentage of the applicable net sales, subject to an annual cap. The net present value of the approval-based milestone payments and sales-based milestone payments, when earned, would be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or the estimated commercial life of the product. Accretion of interest on the liabilities to pay Abingworth will be recognized as interest expense in Other (income)/deductions net. Royalties on net sales will be recorded as Cost of sales when the related product sales occur.

Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives

A. Realigning Our Cost Base Program

In the fourth quarter of 2023, we announced that we launched a multi-year, enterprise-wide cost realignment program that aims to realign our costs with our longer-term revenue expectations. In the second quarter of 2025, we identified additional productivity opportunities to further reduce costs primarily in SI&A, driven in large part by enhanced digital enablement, including automation and AI, and simplification of business processes.

We expect costs associated with these components of the program to be incurred through 2027 and to total approximately $4.7 billion, representing primarily cash expenditures for severance, implementation, exit, and digital enablement costs, as well as non-cash asset write downs of which $3.4 billion is associated with our Biopharma segment.

In the third quarter of 2026, we identified additional productivity enhancements from technology and simplification efforts across our commercial, R&D and enabling functions designed to further reduce costs in SI&A. We expect one-time costs to achieve the additional savings to be incurred through 2029 and to total approximately $2.0 billion, primarily representing cash

11

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

expenditures for digital enablement, implementation and severance of which $800 million is associated with our Biopharma segment.

Additionally, in connection with our efforts to simplify the structure and sharpen the focus of our R&D organization, in the first quarter of 2025, we expanded this program after having identified additional opportunities to drive improvements in productivity and operational efficiencies through enhanced digital enablement, including automation and AI, and simplification of business processes. We expect costs to implement these initiatives to be incurred through 2026 and to total approximately $600 million, primarily representing cash expenditures for severance, digital enablement and implementation, all of which is associated with our Biopharma segment. The majority of these costs were recorded in 2025, with cash outlays expected primarily through 2026.

We expect costs associated with all the components of this program to total approximately $7.3 billion of which $4.8 billion is associated with the Biopharma segment.

From the start of this program through June 28, 2026, we incurred total costs of $4.9 billion, of which $3.8 billion is associated with our Biopharma segment (including $3.3 billion of restructuring charges).

B. Manufacturing Optimization Program

In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which includes operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is primarily focused on operational efficiencies, and we expect costs for this first phase to total approximately $1.4 billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment.

In the third quarter of 2026, we announced the next phase of the program, with a focus on network structure changes, product portfolio enhancements and additional operational efficiencies. The one-time costs to achieve the savings associated with this phase of the program are expected to be approximately $4.0 billion, substantially all associated with our Biopharma segment, with approximately 60% of non-cash expenditures for accelerated depreciation and asset write-downs and 40% of cash expenditures for severance, implementation and exit costs. The costs to achieve these savings are expected to be incurred through 2029.

We expect costs associated with both phases of this program to total approximately $5.4 billion, substantially all of which is associated with the Biopharma segment.

From the start of this program through June 28, 2026, we incurred total costs of $1.1 billion, substantially all of which relates to our Biopharma segment (including $824 million of restructuring charges). The costs were recorded primarily through 2025, with cash outlays expected primarily through 2029.

12

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

C. Key Activities

The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:

Three Months EndedSix Months Ended

(MILLIONS)June 28,

2026June 29,

2025June 28,

2026June 29,

2025

Restructuring charges/(credits):

Employee terminations$354 $(148)$369 $236

Asset impairments54 44 82 217

Exit costs

10 30 17 94

Restructuring charges/(credits)(a)

419 (74)468 547

Integration costs and other(b)

38 56 89 113

Restructuring charges and certain acquisition-related costs457 (18)557 660

Net periodic benefit costs/(credits) recorded in Other (income)/deductions net

(5)(9)(2)(68)

Inventory write-offs recorded in Cost of sales

46 46

Additional depreciation asset restructuring recorded in Cost of sales(c)

10 4 14 7

Implementation costs recorded in our condensed consolidated statements of operations as follows(d):

Cost of sales25 26 40 46

Selling, informational and administrative expenses56 14 91 20

Research and development expenses63 39 102 62

Total implementation costs144 78 233 128

Total costs associated with acquisitions and cost-reduction/productivity initiatives$653 $54 $848 $727

(a)Primarily represents cost-reduction initiatives. Amounts associated with our Biopharma segment: (i) charges of $390 million for the three months ended June 28, 2026 (including charges of $417 million for our Realigning our Cost Base Program and credits of $29 million for our Manufacturing Optimization Program), (ii) charges of $421 million for the six months ended June 28, 2026 (including charges of $464 million for our Realigning our Cost Base Program and credits of $52 million for our Manufacturing Optimization Program), (iii) credits of $406 million for the three months ended June 29, 2025 (including credits of $408 million for our Manufacturing Optimization Program and $25 million for our Realigning our Cost Base Program) and (iv) charges of $211 million for the six months ended June 29, 2025 (including charges of $562 million for our Realigning our Cost Base Program and credits of $412 million for our Manufacturing Optimization Program). For 2025, Employee terminations included revisions of estimates of previously recorded accruals for severance benefits, driven in large part by higher-than-expected voluntary attrition.

(b)Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.

(c)Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.

(d)Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.

The following summarizes the components and changes in restructuring accruals:

(MILLIONS)Employee

Termination

CostsAsset

Impairment

ChargesExit CostsAccrual

Balance, December 31, 2025(a)

$1,783 $ $127 $1,910

Provision

369 82 17 468

Utilization and other(b)

(577)(82)(36)(695)

Balance, June 28, 2026(c)

$1,575 $ $107 $1,682

(a)Included in Other current liabilities ($1.4 billion) and Other noncurrent liabilities ($466 million).

(b)Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.

(c)Included in Other current liabilities ($972 million) and Other noncurrent liabilities ($710 million).

13

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 4. Other (Income)/Deductions Net

Components of Other (income)/deductions net include:

Three Months EndedSix Months Ended

(MILLIONS)June 28,

2026June 29,

2025June 28,

2026June 29,

2025

Interest income$(113)$(156)$(228)$(299)

Interest expense667 654 1,336 1,308

Net interest expense

554 498 1,108 1,009

Net (gains)/losses recognized during the period on equity securities

37 (75)46 295

Net periodic benefit costs/(credits) other than service costs(83)(101)(155)(260)

Certain legal matters, net(a)

842 422 1,033 564

Certain asset impairments(b)

4,325 93 4,325 317

Net gain from the sale of investment in ViiV(c)

(1,870) (1,870)

Changes in fair value of contingent consideration liabilities(d)

255 34 550 42

Other, net(e)

(344)(131)(460)(275)

Other (income)/deductions net$3,716 $739 $4,577 $1,692

(a)The amounts for the second quarter and first six months of 2026 and 2025 primarily include certain product liability and other legal expenses.

(b)The amounts for the second quarter and first six months of 2026 represent intangible asset impairment charges associated with our Biopharma segment, composed of: (i) $3.8 billion in impairments of IPR&D assets, associated with a Phase 3 study for sigvotatug vedotin for the second line treatment of metastatic non-squamous NSCLC, reflecting unfavorable clinical trial results, and (ii) $525 million for Oxbryta (voxelotor) developed technology rights, after engaging with the FDA in July 2026 to discuss their assessment of data and analyses, and it was determined there was no viable pathway to return Oxbryta to the market in the U.S. The amount for the first six months of 2025 primarily included an intangible asset impairment charge associated with our Biopharma segment of $210 million for a Phase 2 indefinite-lived out-licensed asset that was discontinued by our out-licensing partner.

(c)See Note 2C.

(d)See Notes 1D and 16D in our 2025 Form 10-K and Note 7A.

(e)The amounts for the second quarter and first six months of 2026 include, among other things, dividend income of $98 million and $180 million, respectively, from our previous investment in ViiV. The amounts for the second quarter and first six months of 2025 included, among other things, dividend income of $73 million and $111 million, respectively, from our previous investment in ViiV.

Additional information about the intangible assets that were impaired during 2026 follows:

Six Months Ended

Fair Value(a)

June 28, 2026

(MILLIONS)AmountLevel 1Level 2Level 3Impairment

IPR&D(b)

$5,600 $ $ $5,600 $3,800

Developed technology rights(b)

525

Total

$5,600 $ $ $5,600 $4,325

(a)The fair value amount reflects the remaining fair value for the asset that has been impaired as of the date of impairment, as this asset is not measured at fair value on a recurring basis. See Note 1E in our 2025 Form 10-K.

(b)Reflects intangible assets written down to fair value in 2026. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows for the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory factors on the product; and assumptions about the probability of technical and regulatory success (PTRS) of ongoing clinical trials, the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.

For additional information on identifiable intangible assets, see Note 9.

Note 5. Tax Matters

A. Taxes on Income/(Loss) from Continuing Operations

Our effective tax rate for continuing operations was 62.4% for the second quarter of 2026, compared to 4.6% for the second quarter of 2025, and was 2.1% for the first six months of 2026, compared to (0.8)% for the first six months of 2025. The higher effective tax rate for the second quarter of 2026, compared to the second quarter of 2025, reflects a tax benefit on the pre-tax loss resulting from changes in the jurisdictional mix of earnings, primarily due to intangible asset impairments. The higher effective tax rate for the first six months of 2026, compared to the first six months of 2025, was primarily due to changes in the jurisdictional mix of earnings as well as the non-recurrence of favorable global income tax resolutions.

14

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

We elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, to pay our initial estimated $15 billion repatriation tax liability on accumulated post-1986 foreign earnings (Transition Tax liability) over eight years through 2026. The eighth and final annual installment was paid by its April 15, 2026 due date.

See Note 5A in our 2025 Form 10-K for information on our income taxes paid (net of refunds received).

B. Tax Contingencies

We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation.

The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS. Tax years 2019-2022 are under audit by the IRS; tax years 2023-2026 are open but not under audit, and all other tax years are closed. We also have open audit years and certain related audits, appeals and investigations in certain major international tax jurisdictions dating back to 2016.

See Note 5D in our 2025 Form 10-K.

C. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)

Components of Tax provision/(benefit) on other comprehensive income/(loss) include:

Three Months EndedSix Months Ended

(MILLIONS)June 28,

2026June 29,

2025June 28,

2026June 29,

2025

Foreign currency translation adjustments, net(a)

$37 $(269)$112 $(372)

Unrealized holding gains/(losses) on derivative financial instruments, net21 (48)16 (82)

Reclassification adjustments for (gains)/losses included in net income/(loss)1 (32)7 (87)

22 (80)23 (169)

Unrealized holding gains/(losses) on available-for-sale securities, net(7)21 (2)17

Reclassification adjustments for (gains)/losses included in net income/(loss)3 (10)5 9

(4)10 3 26

Reclassification adjustments related to amortization of prior service costs and other, net(2)(6)(3)(13)

Reclassification adjustments related to curtailments of prior service costs and other, net (1)(1)(10)

(2)(7)(5)(23)

Tax provision/(benefit) on other comprehensive income/(loss)$53 $(347)$134 $(538)

(a)Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that are expected to be held indefinitely.

Note 6. Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests

The following summarizes the changes, net of tax, in Accumulated other comprehensive loss:

Net Unrealized Gains/(Losses)Benefit Plans

(MILLIONS)Foreign Currency Translation Adjustments(a)

Derivative Financial InstrumentsAvailable-For-Sale SecuritiesPrior Service (Costs)/Credits and OtherAccumulated Other Comprehensive Income/(Loss)

Balance, January 1, 2026

$(7,796)$(321)$(28)$75 $(8,069)

Other comprehensive income/(loss)(b)

785 60 20 (13)852

Balance, June 28, 2026$(7,011)$(261)$(7)$62 $(7,218)

(a)Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests.

(b)Foreign currency translation adjustments include net gains/(losses) related to the impact of our net investment hedging program.

15

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Note 7. Financial Instruments

A. Fair Value Measurements

Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis and Fair Value Hierarchy:

June 28, 2026December 31, 2025

(MILLIONS)TotalLevel 1Level 2Level 3TotalLevel 1Level 2Level 3

Financial assets:

Short-term investments

Equity securities with readily determinable fair value(a)

$1,630 $ $1,630 $ $2,596 $ $2,596 $

Available-for-sale debt securities:

Government and agency non-U.S.

3,989 3,989 4,859 4,859

Government and agency U.S.

1,909 1,909 3,030 3,030

Corporate and other

1,384 1,384 1,294 1,294

7,281 7,281 9,183 9,183

Total short-term investments8,911 8,911 11,779 11,779

Other current assets

Derivative assets:

Interest rate contracts

5 5

Foreign exchange contracts

466 466 416 416

Total other current assets471 471 416 416

Long-term investments

Equity securities with readily determinable fair values(b)

551 551 642 642

Available-for-sale debt securities:

Government and agency non-U.S.

1 1

Corporate and other

1 1

Total long-term investments551 551 642 642 1

Other noncurrent assets

Derivative assets:

Interest rate contracts

21 21 52 52

Foreign exchange contracts

164 164 64 64

Total derivative assets185 185 116 116

Insurance contracts(c)

1,073 1,073 999 999

Total other noncurrent assets1,258 1,258 1,115 1,115

Total assets$11,191 $551 $10,640 $ $13,953 $642 $13,311 $

Financial liabilities:

Other current liabilities

Derivative liabilities:

Interest rate contracts$9 $ $9 $ $16 $ $16 $

Foreign exchange contracts

225 225 412 412

Contingent consideration liabilities(d)

96 96 95 95

Total other current liabilities330 234 96 523 428 95

Other noncurrent liabilities

Derivative liabilities:

Interest rate contracts277 277 215 215

Foreign exchange contracts

770 770 815 815

Contingent consideration liabilities(d)

2,163 2,163 1,695 1,695

Total other noncurrent liabilities3,211 1,048 2,163 2,725 1,030 1,695

Total liabilities$3,541 $ $1,281 $2,259 $3,248 $ $1,458 $1,790

(a)Includes money market funds primarily invested in U.S. Treasury and government debt.

(b)Long-term equity securities of $120 million as of June 28, 2026 and $146 million as of December 31, 2025 were held in restricted trusts for U.S. non-qualified employee benefit plans.

(c)Includes life insurance policies held in restricted trusts for U.S. non-qualified employee benefit plans. The underlying invested assets in these contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in Other (income)/deductions net (see Note 4).

(d)Includes the fair value of contingent consideration associated with the acquisition of Metsera and certain prior business combinations. Fair value is estimated by using a probability-weighted discounted cash flow approach (see Notes 1D and 16D in our 2025 Form 10-K and Note 2A for additional information on contingent consideration liabilities).

16

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

The following provides the changes in our contingent consideration liabilities valued using significant unobservable inputs:

Six Months Ended

(MILLIONS)June 28,

2026June 29,

2025

Fair value, beginning$1,790 $517

Changes in estimated fair value(a)

550 42

Additions

Settlements and other

(81)(51)

Transfer into/(out of) Level 3

Fair value, ending$2,259 $508

(a)Reported in Other (income)/deductions net. See Note 4. The amount in the first six months of 2026 is primarily related to our acquisition of Metsera.

Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis The carrying value of Long-term debt, excluding the current portion, was $60 billion as of June 28, 2026 and $62 billion as of December 31, 2025. The estimated fair value of such debt, using a market approach and Level 2 inputs, was $58 billion as of June 28, 2026 and $60 billion as of December 31, 2025.

The differences between the estimated fair values and carrying values of held-to-maturity debt securities, private equity securities, long-term receivables and short-term borrowings not measured at fair value on a recurring basis were not significant as of June 28, 2026 and December 31, 2025. The fair value measurements of our held-to-maturity debt securities and short-term borrowings are based on Level 2 inputs. The fair value measurements of our long-term receivables and private equity securities are based on Level 3 inputs.

B. Investments

Total Short-Term and Long-Term Investments

The following summarizes our investments by classification type:

(MILLIONS)June 28,

2026 December 31, 2025

Short-term investments

Equity securities with readily determinable fair values

$1,630 $2,596

Available-for-sale debt securities7,281 9,183

Held-to-maturity debt securities1,811 675

Total Short-term investments$10,723 $12,454

Long-term investments

Equity securities with readily determinable fair values(a)

$551 $642

Available-for-sale debt securities 1

Held-to-maturity debt securities49 48

Private equity securities at cost(a)

718 696

Equity-method investments241 235

Total Long-term investments$1,559 $1,621

(a)Represent investments in the life sciences sector.

Debt Securities

Our investment portfolio consists of investment-grade debt securities issued across diverse governments, corporate and financial institutions:

June 28, 2026December 31, 2025

Gross Unrealized Maturities (in Years)

Gross Unrealized

(MILLIONS)Amortized CostGainsLossesFair ValueWithin 1Over 1

to 5Over 5Amortized CostGainsLossesFair Value

Available-for-sale debt securities

Government and agency non-U.S.

$3,997 $4 $(12)$3,989 $3,989 $ $ $4,890 $3 $(34)$4,859

Government and agency U.S.

1,909 1,909 1,909 3,030 3,030

Corporate and other1,383 1 1,384 1,384 1,295 (1)1,294

Held-to-maturity debt securities

Corporate, time deposits and other

865 865 817 9 39 487 487

Government and agency non-U.S.

996 996 994 1 236 236

Total debt securities$9,150 $5 $(13)$9,142 $9,093 $9 $40 $9,938 $3 $(35)$9,906

17

PFIZER INC. AND SUBSIDIARY COMPANIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

Any expected credit losses to these portfolios would be immaterial to our financial statements.

Equity Securities

The following presents the calculation of the portion of unrealized (gains)/losses that relates to equity securities, excluding equity-method investments, held at the reporting date:

Three Months EndedSix Months Ended

(MILLIONS)June 28,

2026June 29,

2025June 28,

2026June 29,

2025

Net (gains)/losses recognized during the period on equity securities(a)

$37 $(75)$46 $295

Less: Net (gains)/losses recognized during the period on equity securities sold during the period(16)(10)(22)(934)

Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date

$53 $(65)$68 $1,230

(a)Reported in Other (income)/deductions net. See Note 4.

Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of June 28, 2026, there were cumulative impairments and downward adjustments of $469 million and upward adjustments of $225 million. Impairments, downward and upward adjustments were not material to our operations in the second quarters and first six months of 2026 and 2025.

C. Short-Term Borrowings

Short-term borrowings include:

(MILLIONS) June 28,

2026 December 31, 2025

Current portion of long-term debt, principal amount$2,607 $3,000

Other short-term borrowings, principal amount(a)

94 157

Total short-term borrowings, principal amount

2,701 3,157

Net unamortized discounts, premiums and debt issuance costs(2)(3)

Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted